Daily Oral Orforglipron for Adults with Obesity
|
Reviewed & translated by Nhi Phuong Quynh Le, B.A
Edited by Dat Tien Nguyen, B.A, ScM. |
Posted on September 29th, 2023
|
Obesity is a high-risk disease and a precursor to several diseases relating to the cardiovascular system. Orforglipron is a glucagonlike peptide-1 (GLP-1) receptor agonist orforglipron that can reduce appetite. However, its efficacy and safety is unknown. Thus, a study was conducted to examine the effectiveness and safety of orforglipron for weight reduction in adults with obesity.
The phase 2 trial included 272 participants who were from 18 to 75 years of age. These individuals had not been diagnosed with diabetes, and they had a mean body weight of 108.7 kg, and their mean BMI was 37.9. The study participants were randomly assigned to receive either placebo or different dosage of orforglipron (12 mg, 24 mg, 36 mg, or 45 mg). The treatment and placebo was given orally once a day for 36 weeks. The effectiveness of orforglipron was assessed based on the percentage of change from the baseline date of participant’s body weight. After 26 weeks of treatment, those in the orforglipron group experienced a mean 8.6% to 12.6% reduction in body weight. The degree of clinical effect positively correlates with the ascending dose of orforglipron. The change in body weight was significantly higher than the 2.0% reduction observed in the placebo group. The change in body weight is also sustainable. At week 36, the mean reduction ranged from between 9.4% and 14.7% in the dosage of orforglipron group, while those in the placebo group only observed a 2.3% reduction. Relating to the safety of orforglipron, all of the side effects were relatively moderate. The most commonly reported adverse events were nausea, constipation, vomiting, diarrhea, and eructation. However, between 10% and 17% of the participants receiving orforglipron had to discontinue due to these adverse effects.
The phase 2 trial included 272 participants who were from 18 to 75 years of age. These individuals had not been diagnosed with diabetes, and they had a mean body weight of 108.7 kg, and their mean BMI was 37.9. The study participants were randomly assigned to receive either placebo or different dosage of orforglipron (12 mg, 24 mg, 36 mg, or 45 mg). The treatment and placebo was given orally once a day for 36 weeks. The effectiveness of orforglipron was assessed based on the percentage of change from the baseline date of participant’s body weight. After 26 weeks of treatment, those in the orforglipron group experienced a mean 8.6% to 12.6% reduction in body weight. The degree of clinical effect positively correlates with the ascending dose of orforglipron. The change in body weight was significantly higher than the 2.0% reduction observed in the placebo group. The change in body weight is also sustainable. At week 36, the mean reduction ranged from between 9.4% and 14.7% in the dosage of orforglipron group, while those in the placebo group only observed a 2.3% reduction. Relating to the safety of orforglipron, all of the side effects were relatively moderate. The most commonly reported adverse events were nausea, constipation, vomiting, diarrhea, and eructation. However, between 10% and 17% of the participants receiving orforglipron had to discontinue due to these adverse effects.